Skip to main content

Table 4 Univariate analysis of hematological indexes and PFS, OS

From: Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

Inspection index

mPFS (95% CI) months

χ2

P

mOS (95% CI), months

χ2

P

WBC (× 109/L)

  < 6.08

4.1 (3.5–4.7)

1.385

0.239

6.9 (6.1–7.7)

0.19

0.889

  ≥ 6.08

3.9 (3.0–4.7)

  

6.6 (5.0–8.2)

  

ANC (× 109/L)

  < 4.16

4.3 (3.7–4.8)

1.218

0.270

6.9 (6.0–7.7)

0.003

0.956

  ≥ 4.16

3.4 (2.6–4.2)

  

6.6 (5.0–8.2)

  

ALC (× 109/L)

  < 1.27

3.7 (3.0–4.4)

3.178

0.075

6.4 (5.2–7.6)

1.761

0.184

  ≥ 1.27

4.3 (3.6–5.1)

  

7.2 (6.2–8.1)

  

AMC (× 109/L)

  < 0.38

4.5 (3.8–5.2)

6.875

0.009

7.1 (6.2–8.1)

2.17

0.141

  ≥ 0.38

3.7 (3.1–4.3)

  

6.4 (5.1–7.6)

  

RBC (× 109/L)

  < 4.09

3.7 (3.0–4.4)

1.178

0.278

6.9 (5.4–8.4)

0.003

0.959

  ≥ 4.09

4.5 (3.7–5.3)

  

6.8 (6.0–7.7)

  

Hb (g/L)

  < 126

3.6 (3.0–4.2)

1.892

0.169

6.3 (5.2–7.4)

1.802

0.179

  ≥ 126

4.6 (3.9–5.3)

  

7.5 (6.5–8.5)

  

PLT (× 109/L)

  < 227

4.1 (3.4–4.8)

0.037

0.848

7.0 (6.3–7.8)

1.108

0.292

  ≥ 227

4.0 (3.4–4.6)

  

6.4 (4.9–7.8)

  

AEC (× 109/L)

  < 0.09

3.7 (3.1–4.4)

0.129

0.720

6.6 (5.3–7.9)

0.3

0.584

  ≥ 0.09

4.3 (3.7–5.0)

  

7.2 (6.4–8.0)

  

ABC (× 109/L)

  < 0.02

4.3 (3.4–5.2)

0.013

0.909

5.9 (3.6–8.3)

0.448

0.503

  ≥ 0.02

4.0 (3.5–4.5)

  

6.8 (6.0–7.7)

  

PAB (mg/L)

  < 206.56

3.7 (3.2–4.3)

2.923

0.087

5.7 (4.7–6.7)

16.734

 < 0.001

  ≥ 206.56

4.4 (3.6–5.2)

  

8.1 (6.7–9.5)

  

ALB (g/L)

  < 40.7

3.4 (2.6–4.2)

6.382

0.012

5.7 (5.0–6.5)

15.642

 < 0.001

  ≥ 40.7

4.5 (3.9–5.2)

  

8.7 (7.6–9.8)

  

NLR

  < 3.26

4.4 (3.6–5.2)

0.923

0.337

7.4 (6.6–8.3)

3.44

0.064

  ≥ 3.26

3.4 (2.7–4.1)

  

5.9 (4.9–7.0)

  

PLR

  < 175.23

4.0 (3.3–4.8)

1.336

0.248

6.9 (5.8–8.0)

1.468

0.226

  ≥ 175.23

4.0 (3.4–4.6)

  

6.6 (5.3–8.0)

  

MLR

  < 0.30

4.5 (3.7–5.3)

3.242

0.072

7.5 (6.6–8.3)

1.789

0.181

  ≥ 0.30

3.5 (2.9–4.1)

  

5.9 (4.8–7.0)

  

PNI

  < 47.3

3.9 (3.1–4.6)

7.095

0.008

5.9 (5.0–6.8)

9.591

0.002

  ≥ 47.3

4.3 (3.5–5.1)

  

8.1 (6.2–10.0)

  

SIRI

  < 1.22

4.4 (3.8–5.1)

6.102

0.014

7.2 (6.5–7.8)

2.379

0.123

  ≥ 1.22

3.4 (2.7–4.1)

  

6.4 (5.2–7.6)

  

NER

  < 47.72

4.5 (3.8–5.3)

1.346

0.246

7.3 (6.5–8.1)

0.766

0.382

  ≥ 47.72

3.4 (2.7–4.1)

  

6.4 (5.0–7.7)

0.19

0.889

  1. PFS Progression-free survival, OS Overall survival, mPFS Median progression-free survival, mOS Median overall survival, WBC White blood cell, ANC Absolute neutrophil counter, ALC Absolute lymphoblastic counter, AMC Absolute monocyte counter, Hb Hemoglobin, RBC Red blood cell, PLT Platelet, AEC Absolute eosinophil count, ABC Absolute basophil count, PAB Prealbumin, ALB Albumin, NLR Neutrophil–lymphocyte ratio, PLR Platelet-lymphocyte ratio, MLR Monocyte-lymphocyte ratio, PNI Prognostic nutritional index, SIRI Systemic inflammatory response index, NER Neutrophil-eosinophil ratio
  2. P < 0.05 is statistically significant
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us